M
Marisa N. Mercadante
Researcher at Cornell University
Publications - 6
Citations - 128
Marisa N. Mercadante is an academic researcher from Cornell University. The author has contributed to research in topics: Coronavirus & Medicine. The author has an hindex of 3, co-authored 3 publications receiving 70 citations.
Papers
More filters
Posted ContentDOI
SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2
Tomer M Yaron,Brook E. Heaton,Tyler Levy,Jared L. Johnson,Tristan X Jordan,Benjamin M. Cohen,Alexander Kerelsky,Ting-Yu Lin,Katarina M. Liberatore,Danielle K. Bulaon,Edward R. Kastenhuber,Marisa N. Mercadante,Kripa Shobana-Ganesh,Long He,Robert E. Schwartz,Shuibing Chen,Harel Weinstein,Oliver Elemento,Elena Piskounova,Benjamin E. Nilsson-Payant,Gina Lee,Joseph D. Trimarco,Kaitlyn N. Burke,Cait E. Hamele,Ryan R. Chaparian,Alfred T. Harding,Aleksandra Tata,Xinyu Zhu,Purushothama Rao Tata,Clare M. Smith,Anthony Possemato,Sasha Tkachev,Peter Hornbeck,Sean A. Beausoleil,Shankara Anand,François Aguet,Gad Getz,Andrew D. Davidson,Kate J. Heesom,Maia Kavanagh-Williamson,David A. Matthews,Benjamin R. tenOever,Lewis C. Cantley,John Blenis,Nicholas S. Heaton +44 more
TL;DR: A genome-wide screen in human lung epithelial cells is performed to identify potential host therapeutic targets and suggests that SRPK1/2-targeted therapies may be an efficacious strategy to prevent or treat COVID-19 and other coronavirus-mediated diseases.
Posted ContentDOI
The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro.
Tomer M. Yaron,Brook E. Heaton,Tyler Levy,Jared L. Johnson,Tristan X. Jordan,Benjamin M. Cohen,Alexander Kerelsky,Ting-Yu Lin,Katarina M. Liberatore,Danielle K. Bulaon,Edward R. Kastenhuber,Marisa N. Mercadante,Kripa Shobana-Ganesh,Long He,Robert E. Schwartz,Shuibing Chen,Harel Weinstein,Olivier Elemento,Elena Piskounova,Benjamin E. Nilsson-Payant,Gina Lee,Joseph D. Trimarco,Kaitlyn N. Burke,Cait E. Hamele,Ryan R. Chaparian,Alfred T. Harding,Aleksandra Tata,Xinyu Zhu,Purushothama Rao Tata,Clare M. Smith,Anthony Possemato,Sasha Tkachev,Peter Hornbeck,Sean A. Beausoleil,Shankara Anand,François Aguet,Gad Getz,Gad Getz,Andrew D. Davidson,Kate J. Heesom,Maia Kavanagh-Williamson,David A. Matthews,Benjamin R. tenOever,Lewis C. Cantley,John Blenis,Nicholas S. Heaton +45 more
TL;DR: The data suggest that repurposing or developing novel host-kinase directed therapies may be an efficacious strategy to prevent or treat COVID-19 and other coronavirus-mediated diseases.
Posted ContentDOI
Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
Edward R. Kastenhuber,Javier A. Jaimes,Jared L. Johnson,Marisa N. Mercadante,Frauke Muecksch,Yiska Weisblum,Yaron Bram,Robert E. Schwartz,Gary R. Whittaker,Lewis C. Cantley +9 more
TL;DR: In this paper, a drug-repurposing screen identified a subset of protease inhibitors that promiscuously inhibited spike cleavage by both transmembrane serine proteases as well as coagulation factors.
Journal ArticleDOI
Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
Edward R. Kastenhuber,Marisa N. Mercadante,Benjamin E. Nilsson-Payant,Jared L. Johnson,Javier A. Jaimes,Frauke Muecksch,Yiska Weisblum,Yaron Bram,Gary R. Whittaker,Benjamin R. tenOever,Robert E. Schwartz,Vasuretha Chandar,Lewis C. Cantley +12 more
TL;DR: This work proposes a model of positive feedback whereby infection-induced hypercoagulation exacerbates SARS-CoV-2 infectivity and identifies a subset of protease inhibitors that promiscuously inhibited spike cleavage by both transmembrane serine proteases and coagulation factors.
Posted ContentDOI
Evolution of host protease interactions among SARS-CoV-2 variants of concern and related coronaviruses
TL;DR: It is shown that substitutions in the S1/S2 cleavage site observed in SARS-CoV-2 variants of concern (VOCs) exhibit divergent interactions with host proteases, including factor Xa and furin.